An Open-Label, Multiple-Dose Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

Daewoong Pharmaceutical Co. LTD.1 site in 1 country36 target enrollmentSeptember 6, 2020

ConditionsDrug-drug Interaction

InterventionsDWC202005, alone DWP14012 + DWC202005 DWP14012 + DWC202005, after multiple doses of DWP14012

DrugsDWC202005, alone DWP14012 + DWC202005 DWP14012 + DWC202005, after multiple doses of DWP14012

Overview

Phase: Phase 1
Intervention: DWC202005, alone
Conditions: Drug-drug Interaction
Sponsor: Daewoong Pharmaceutical Co. LTD.
Enrollment: 36
Locations: 1
Primary Endpoint: Area under the plasma drug concentration-time curve
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers

Registry

clinicaltrials.gov

Start Date

September 6, 2020

End Date

November 21, 2020

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Daewoong Pharmaceutical Co. LTD.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy adults aged 19 to 50 years with BMI between 18.5 kg/m2 and 30.0 kg/m2
•Capable of understanding provided information and complying with protocol requirements
•Provide written informed consent to participate in the study